Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment

Medical Science Monitor

Volumn 18, Issue 12, 2012, Pages

  Sophia Jaeger, Bernadette Anna ^a   Tauer, Josephine Tabea ^a   Ulmer, Anna ^a   Kuhlisch, Eberhard ^a   Roth, Heinz Juergen ^b   Suttorp, Meinolf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Limbach Laboratory   (Germany)

Author keywords

Bone metabolism; Children; Chronic myeloid leukemia; Imatinib

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIFEDIOL; CALCITRIOL; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; DIHYDROPYRIMIDINE DEHYDROGENASE; IMATINIB; MAGNESIUM; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PROCOLLAGEN C PROTEINASE; PYRIDINOLINE; TELOPEPTIDE; VITAMIN D;

ADOLESCENT; ARTICLE; BONE METABOLISM; BONE REMODELING; CHEMILUMINESCENCE IMMUNOASSAY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; HUMAN; HYPERPARATHYROIDISM; MALE; METABOLIC PARAMETERS; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; BENZAMIDES; BONE AND BONES; CALCIFEDIOL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; OSTEOCALCIN; PIPERAZINES; PYRIMIDINES; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 84874779880     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883599     Document Type: Article

References (40)

1. Druker BJ, Guilhot F, O'Brien SG et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006; 355: 2408-17
2. Champagne MA, Capdeville R, Krailo M et al: Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood, 2004; 104: 2655-60
3. Millot F, Guilhot J, Nelken B et al: Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia, 2006; 20: 187-92
4. Schultz KR, Bowman WP, Aledo A et al: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol, 2009; 27: 5175-81
5. Millot F, Baruchel A, Guilhot J et al: Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol, 2011; 29: 2827-32
6. Champagne MA, Fu CH, Chang M et al: Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer, 2011; 57: 56-62
7. Barr RD: Imatinib mesylate in children and adolescents with cancer. Pediatr Blood Cancer, 2010; 55: 18-25
8. Suttorp M, Millot F: Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program, 2010; 2010: 368-76
9. Vandyke K, Fitter S, Dewar AL et al: Dysregulation of bone remodeling by imatinib mesylate. Blood, 2010; 115: 766-74
10. Breccia M, Alimena G: The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. Leuk Res, 2009; 33: 871-75
11. Millot F, Baruchel A, Guilhot J et al: Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial (Abstract). Blood, 2009; 110: 863
12. Shima H, Tokuyama M, Tanizawa A et al: Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr, 2011; 159: 676-81
13. Bansal D, Shava U, Varma N et al: Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer, 2012; 59(3): 481-84
14. Roth HJ, Schmidt-Gayk H, Weber H, Niederau C: Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem, 2008; 45: 153-59
15. Black D, Duncan A, Robins SP: Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem, 1988; 169: 197-203
16. van der Sluis IM, Hop WC, van Leeuwen JP et al: A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults. Horm Res, 2002; 57: 170-79
17. Reiss I, Interrieden D, Kruse K: Bestimmung der knochenspezifischen alkalischen phosphatase bei Störungen des Kalziumstoffwechsels im Kindesalter. Monatsschr Kinderheilkd, 1996;144: 885-90 [in German]
18. Rauchenzauner M, Schmid A, Heinz-Erian P et al: Sex-and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab, 2007; 92: 443-49
19. Berman E, Nicolaides M, Maki RG et al: Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med, 2006; 354(19): 2006-13
20. Osorio S, Noblejas AG, Durán A, Steegmann JL: Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol, 2007; 82: 394-95
21. O'Sullivan S, Horne A, Wattie D et al: Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab, 2009; 94: 1131-36
22. Jönsson S, Olsson B, Ohlsson C et al: Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica, 2008; 93: 1101-3
23. Seeman E, Delmas PD: Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med, 2006; 354: 2250-61
24. el-Hajj Fuleihan G, Klerman EB, Brown EN et al: The parathyroid hormone circadian rhythm is truly endogenous--a general clinical research center study. J Clin Endocrinol Metab, 1997; 82: 281-86
25. Gertz BJ, Clemens JD, Holland SD et al: Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int, 1998; 63: 102-6
26. Hannon R, Eastell R: Preanalytical variability of biochemical markers of bone turnover (Review). Osteoporos Int, 2000; 11(Suppl.6): 30-44
27. Holick MF: Vitamin D deficiency. N Engl J Med, 2007; 357: 266-81
28. Marx SJ: Hyperparathyroid and hypoparathyroid disorders. N Engl J Med, 2000; 343: 1863-75
29. Rauch F, Schönau E, Woitge H, Remer T, Seibel M: Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp Clin Endocrinol, 1994; 102: 94-97
30. Szulc P, Seeman E, Delmas PD: Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int, 2000; 11: 281-94
31. Crofton PM, Evans N, Taylor MR, Holland CV: Procollagen type I amino-terminal propeptide: pediatric reference data and relationship with procollagen type I carboxyl-terminal propeptide. Clin Chem, 2004; 50: 2173-76
32. Rauch F, Schoenau E: Markers of bone metabolism-use in pediatrics (Review). Clin Lab, 1997; 43: 743-52
33. Crofton PM, Evans N, Taylor MR, Holland CV: Serum CrossLaps: pediatric reference intervals from birth to 19 years of age. Clin Chem, 2002; 48: 671-73
34. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N et al: Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone, 2000; 26: 505-11
35. Marowska J, Kobylińska M, Lukaszkiewicz J et al: Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: normal values and clinical application. Bone, 1996; 19: 669-77
36. Watts NB: Clinical utility of biochemical markers of bone remodeling. Clin Chem, 1999; 45: 1359-68
37. Mariani S, Giona F, Basciani S et al: Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet, 2008; 372: 111-12
38. Schmid H, Jaeger BA, Lohse J, Suttorp M: Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica, 2009; 94: 1177-79
39. Legros L, Breuil V, Ferrari P et al: Hypophosphatemia Observed in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate (Gleevec(R) Is Related to Digestive Side-Effects (Abstract). Blood, 2006; 108: 4765
40. Yang L, Grey V: Pediatric reference intervals for bone markers. Clin Biochem, 2006; 39: 561-68